The stock of AstraZeneca PLC (AZN) has seen a -1.61% decrease in the past week, with a -2.30% drop in the past month, and a 7.58% flourish in the past quarter. The volatility ratio for the week is 1.58%, and the volatility levels for the past 30 days are at 1.24% for AZN. The simple moving average for the last 20 days is -0.64% for AZN stock, with a simple moving average of 12.39% for the last 200 days.
Is It Worth Investing in AstraZeneca PLC (NASDAQ: AZN) Right Now?
AstraZeneca PLC (NASDAQ: AZN) has a price-to-earnings ratio of 49.12x that is above its average ratio. Additionally, the 36-month beta value for AZN is 0.53. There are mixed opinions on the stock, with 23 analysts rating it as a “buy,” 2 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The public float for AZN is 2.99B and currently, short sellers hold a 0.19% ratio of that float. The average trading volume of AZN on May 24, 2023 was 4.01M shares.
AZN) stock’s latest price update
AstraZeneca PLC (NASDAQ: AZN)’s stock price has plunge by -0.51relation to previous closing price of 74.45. Nevertheless, the company has seen a -1.61% plunge in its stock price over the last five trading sessions. The Wall Street Journal reported on 10/11/22 that AstraZeneca Looks to New Drugs as Covid-Vaccine Demand Wanes
AZN Trading at 2.93% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.25% of loss for the given period.
Volatility was left at 1.24%, however, over the last 30 days, the volatility rate increased by 1.58%, as shares sank -2.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.64% upper at present.
During the last 5 trading sessions, AZN fell by -1.61%, which changed the moving average for the period of 200-days by +12.18% in comparison to the 20-day moving average, which settled at $74.47. In addition, AstraZeneca PLC saw 9.25% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- +11.41 for the present operating margin
- +63.36 for the gross margin
The net margin for AstraZeneca PLC stands at +7.41. The total capital return value is set at 7.69, while invested capital returns managed to touch 5.30. Equity return is now at value 13.10, with 4.90 for asset returns.
Based on AstraZeneca PLC (AZN), the company’s capital structure generated 78.93 points at debt to equity in total, while total debt to capital is 44.11. Total debt to assets is 30.30, with long-term debt to equity ratio resting at 63.96. Finally, the long-term debt to capital ratio is 35.75.
When we switch over and look at the enterprise to sales, we see a ratio of 5.64, with the company’s debt to enterprise value settled at 0.13. The receivables turnover for the company is 4.88 and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
In conclusion, AstraZeneca PLC (AZN) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
